David J. Wambeke
CIK: 0001971798
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Aug 28, 2026NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Award(A)DirectOption to Purchase Common Stock
35K shares- - Aug 27, 2026NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Purchase(P)Direct33.3K shares at avg. $2.01$67K - Mar 1, 2026NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Purchase(P)Direct1M shares at avg. $0.67$670K - Mar 1, 2026NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Award(A)DirectOption to Purchase Common Stock
500K shares- - Jun 1, 2025DMAC
DiaMedica Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
250K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 28, 2026 |  NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | Award(A) Option to Purchase Common Stock | 35,000 | - | - | Direct |
| Aug 27, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | Purchase(P) | 33,333 | $2.01 | $66,999 | Direct |
| Mar 1, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | Purchase(P) | 1,000,000 | $0.67 | $670,400 | Direct |
| Mar 1, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | Award(A) Option to Purchase Common Stock | 500,000 | - | - | Direct |
| Jun 1, 2025 |  DMAC DiaMedica Therapeutics Inc. | Award(A) Stock Option (right to buy) | 250,000 | - | - | Direct |
1-5 of 5 transactions
About Wambeke David J.
Wambeke David J. (SEC CIK 0001971798) files insider reports with the SEC as Chief Business Officer of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) and Chief Business Officer of DiaMedica Therapeutics Inc. (DMAC).
Signal8 holds 4 ownership filings by Wambeke David J. (1 Form 3, 3 Form 4), filed between Jun 3, 2025 and Sep 8, 2026. Those filings report 5 transactions, from Jun 1, 2025 to Aug 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wambeke David J.'s filings is in EDEN PRAIRIE, MN.
Recent filings by Wambeke David J.
- Aug 28, 2026: Grant or award of NMTC derivative securities (Form 4, code A).
- Aug 27, 2026: Open-market purchase of NMTC shares (Form 4, code P).
- Mar 1, 2026: Open-market purchase of NMTC shares (Form 4, code P).
- Mar 1, 2026: Grant or award of NMTC derivative securities (Form 4, code A).
- Jun 1, 2025: Grant or award of DMAC derivative securities (Form 4, code A).
Other insiders filing for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
- Johns Emily J., Chief Administrative Officer
- Volker Christopher, Chief Financial Officer
- Christianson Mark, Market Development Director
- Mertens Steve, Chief Technology Officer
- Rosa David A, CEO & President
- Pratt Brian, 10% Owner